Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
|Articles|April 15, 2008
The American Journal of Managed Care
- April 2008
- Volume 14
- Issue 4
Furst, DE; Khanna, D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217)
Advertisement
After the publication of our December 2007 supplement, “Health-related Quality of Life in Rheumatoid Arthritis,” the Editors learned that several authors were not given the opportunity to review the final proofs of their manuscripts. As a result, errors were subsequently identified. The co-author’s name was inadvertently omitted from the Introduction. The correct byline for the Introduction should read: Daniel E. Furst, MD, and Dinesh Khanna, MD.
Click here
to view the corrected version of this article.
Articles in this issue
over 18 years ago
Furst DE, Khanna D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217.over 18 years ago
Strand V, Singh JA. (Am J Manag Care. 2007;[suppl 9]:S237-S251.over 18 years ago
Strand V, Singh JA. (Am J Manag Care. 2007;13[suppl 9]:S237-S251)over 18 years ago
Association of Insurance Coverage With Chlamydia ScreeningAdvertisement
Related to this article
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5